(MDLZ) Mondelez International - Overview
Exchange: NASDAQ •
Country: United States •
Currency: USD •
Type: Common Stock •
ISIN: US6092071058
Stock: Biscuits, Chocolates, Candies, Beverages, Snacks
Total Rating 38
Risk 63
Buy Signal -1.05
| Risk 5d forecast | |
|---|---|
| Volatility | 23.7% |
| Relative Tail Risk | -1.92% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -0.84 |
| Alpha | -21.11 |
| Character TTM | |
|---|---|
| Beta | 0.045 |
| Beta Downside | -0.048 |
| Drawdowns 3y | |
|---|---|
| Max DD | 29.14% |
| CAGR/Max DD | -0.11 |
EPS (Earnings per Share)
Revenue
Description: MDLZ Mondelez International March 05, 2026
Mondelez International, Inc. (MDLZ) manufactures and sells snack foods and beverages globally. The companys product categories include biscuits, baked snacks, chocolates, gums, and candies. This business model focuses on established brands and global distribution.
MDLZ distributes products through diverse channels, including traditional retail (supermarkets, convenience stores) and e-commerce platforms. The packaged foods sector is characterized by high brand loyalty and extensive supply chains.
Key brands include Oreo, Cadbury Dairy Milk, and Toblerone. The company serves a broad customer base, from large retail chains to individual consumers via direct-to-consumer websites. For more detailed financial analysis, consider exploring ValueRay.
Headlines to watch out for
- Global snack demand drives revenue growth
- Commodity price volatility impacts production costs
- Foreign exchange rates affect international earnings
- Regulatory changes in food labeling increase compliance burden
Piotroski VR‑10 (Strict, 0-10) 6.5
| Net Income: 2.45b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.05 > 0.02 and ΔFCF/TA -0.62 > 1.0 |
| NWC/Revenue: -23.13% < 20% (prev -17.31%; Δ -5.82% < -1%) |
| CFO/TA 0.06 > 3% & CFO 4.51b > Net Income 2.45b |
| Net Debt (20.28b) to EBITDA (4.87b): 4.16 < 3 |
| Current Ratio: 0.59 > 1.5 & < 3 |
| Outstanding Shares: last quarter (1.29b) vs 12m ago -3.58% < -2% |
| Gross Margin: 28.38% > 18% (prev 0.39%; Δ 2.80k% > 0.5%) |
| Asset Turnover: 55.06% > 50% (prev 53.20%; Δ 1.86% > 0%) |
| Interest Coverage Ratio: 9.65 > 6 (EBITDA TTM 4.87b / Interest Expense TTM 364.0m) |
Altman Z'' 1.76
| A: -0.12 (Total Current Assets 12.95b - Total Current Liabilities 21.86b) / Total Assets 71.49b |
| B: 0.51 (Retained Earnings 36.41b / Total Assets 71.49b) |
| C: 0.05 (EBIT TTM 3.51b / Avg Total Assets 69.99b) |
| D: 0.55 (Book Value of Equity 25.05b / Total Liabilities 45.60b) |
| Altman-Z'' Score: 1.76 = BBB |
Beneish M -2.71
| DSRI: 0.95 (Receivables 4.86b/4.81b, Revenue 38.54b/36.44b) |
| GMI: 1.38 (GM 28.38% / 39.12%) |
| AQI: 1.00 (AQ_t 0.66 / AQ_t-1 0.66) |
| SGI: 1.06 (Revenue 38.54b / 36.44b) |
| TATA: -0.03 (NI 2.45b - CFO 4.51b) / TA 71.49b) |
| Beneish M-Score: -2.71 (Cap -4..+1) = A |
What is the price of MDLZ shares?
As of March 16, 2026, the stock is trading at USD 55.36 with a total of 9,973,571 shares traded.
Over the past week, the price has changed by -6.03%, over one month by -12.32%, over three months by +2.07% and over the past year by -12.48%.
Over the past week, the price has changed by -6.03%, over one month by -12.32%, over three months by +2.07% and over the past year by -12.48%.
Is MDLZ a buy, sell or hold?
Mondelez International has received a consensus analysts rating of 4.07.
Therefore, it is recommended to buy MDLZ.
- StrongBuy: 11
- Buy: 8
- Hold: 9
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the MDLZ price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 66.9 | 20.8% |
| Analysts Target Price | 66.9 | 20.8% |
MDLZ Fundamental Data Overview March 16, 2026
P/E Trailing = 30.8995
P/E Forward = 18.9036
P/S = 1.9554
P/B = 2.8973
P/EG = 5.4835
Revenue TTM = 38.54b USD
EBIT TTM = 3.51b USD
EBITDA TTM = 4.87b USD
Long Term Debt = 17.22b USD (from longTermDebt, last quarter)
Short Term Debt = 3.98b USD (from shortTermDebt, last quarter)
Debt = 22.40b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 20.28b USD (from netDebt column, last quarter)
Enterprise Value = 95.63b USD (75.36b + Debt 22.40b - CCE 2.12b)
Interest Coverage Ratio = 9.65 (Ebit TTM 3.51b / Interest Expense TTM 364.0m)
EV/FCF = 29.56x (Enterprise Value 95.63b / FCF TTM 3.23b)
FCF Yield = 3.38% (FCF TTM 3.23b / Enterprise Value 95.63b)
FCF Margin = 8.39% (FCF TTM 3.23b / Revenue TTM 38.54b)
Net Margin = 6.36% (Net Income TTM 2.45b / Revenue TTM 38.54b)
Gross Margin = 28.38% ((Revenue TTM 38.54b - Cost of Revenue TTM 27.60b) / Revenue TTM)
Gross Margin QoQ = 28.16% (prev 26.81%)
Tobins Q-Ratio = 1.34 (Enterprise Value 95.63b / Total Assets 71.49b)
Interest Expense / Debt = 0.24% (Interest Expense 54.0m / Debt 22.40b)
Taxrate = 28.06% (261.0m / 930.0m)
NOPAT = 2.53b (EBIT 3.51b * (1 - 28.06%))
Current Ratio = 0.59 (Total Current Assets 12.95b / Total Current Liabilities 21.86b)
Debt / Equity = 0.87 (Debt 22.40b / totalStockholderEquity, last quarter 25.84b)
Debt / EBITDA = 4.16 (Net Debt 20.28b / EBITDA 4.87b)
Debt / FCF = 6.27 (Net Debt 20.28b / FCF TTM 3.23b)
Total Stockholder Equity = 26.00b (last 4 quarters mean from totalStockholderEquity)
RoA = 3.50% (Net Income 2.45b / Total Assets 71.49b)
RoE = 9.43% (Net Income TTM 2.45b / Total Stockholder Equity 26.00b)
RoCE = 8.13% (EBIT 3.51b / Capital Employed (Equity 26.00b + L.T.Debt 17.22b))
RoIC = 5.41% (NOPAT 2.53b / Invested Capital 46.74b)
WACC = 4.73% (E(75.36b)/V(97.76b) * Re(6.08%) + D(22.40b)/V(97.76b) * Rd(0.24%) * (1-Tc(0.28)))
Discount Rate = 6.08% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: -100.0 | Cagr: -2.68%
[DCF] Terminal Value 85.93% ; FCFF base≈3.35b ; Y1≈3.22b ; Y5≈3.15b
[DCF] Fair Price = 57.82 (EV 94.40b - Net Debt 20.28b = Equity 74.12b / Shares 1.28b; r=5.90% [WACC]; 5y FCF grow -5.18% → 2.90% )
EPS Correlation: -10.68 | EPS CAGR: -4.03% | SUE: 0.44 | # QB: 0
Revenue Correlation: 81.61 | Revenue CAGR: 8.37% | SUE: 2.15 | # QB: 1
EPS next Quarter (2026-06-30): EPS=0.69 | Chg7d=+0.000 | Chg30d=+0.000 | Revisions Net=-10 | Analysts=16
EPS current Year (2026-12-31): EPS=3.04 | Chg7d=+0.000 | Chg30d=-0.024 | Revisions Net=-22 | Growth EPS=+4.3% | Growth Revenue=+3.1%
EPS next Year (2027-12-31): EPS=3.39 | Chg7d=-0.004 | Chg30d=-0.013 | Revisions Net=-9 | Growth EPS=+11.3% | Growth Revenue=+3.2%
[Analyst] Revisions Ratio: -0.83 (1 Up / 11 Down within 30d for Next Quarter)
[Growth] Implied Growth Rate = 4.7% (Discount Rate 7.9% - Earnings Yield 3.2%)
[Growth] Growth Spread = -2.4% (Analyst 2.3% - Implied 4.7%)
P/E Forward = 18.9036
P/S = 1.9554
P/B = 2.8973
P/EG = 5.4835
Revenue TTM = 38.54b USD
EBIT TTM = 3.51b USD
EBITDA TTM = 4.87b USD
Long Term Debt = 17.22b USD (from longTermDebt, last quarter)
Short Term Debt = 3.98b USD (from shortTermDebt, last quarter)
Debt = 22.40b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 20.28b USD (from netDebt column, last quarter)
Enterprise Value = 95.63b USD (75.36b + Debt 22.40b - CCE 2.12b)
Interest Coverage Ratio = 9.65 (Ebit TTM 3.51b / Interest Expense TTM 364.0m)
EV/FCF = 29.56x (Enterprise Value 95.63b / FCF TTM 3.23b)
FCF Yield = 3.38% (FCF TTM 3.23b / Enterprise Value 95.63b)
FCF Margin = 8.39% (FCF TTM 3.23b / Revenue TTM 38.54b)
Net Margin = 6.36% (Net Income TTM 2.45b / Revenue TTM 38.54b)
Gross Margin = 28.38% ((Revenue TTM 38.54b - Cost of Revenue TTM 27.60b) / Revenue TTM)
Gross Margin QoQ = 28.16% (prev 26.81%)
Tobins Q-Ratio = 1.34 (Enterprise Value 95.63b / Total Assets 71.49b)
Interest Expense / Debt = 0.24% (Interest Expense 54.0m / Debt 22.40b)
Taxrate = 28.06% (261.0m / 930.0m)
NOPAT = 2.53b (EBIT 3.51b * (1 - 28.06%))
Current Ratio = 0.59 (Total Current Assets 12.95b / Total Current Liabilities 21.86b)
Debt / Equity = 0.87 (Debt 22.40b / totalStockholderEquity, last quarter 25.84b)
Debt / EBITDA = 4.16 (Net Debt 20.28b / EBITDA 4.87b)
Debt / FCF = 6.27 (Net Debt 20.28b / FCF TTM 3.23b)
Total Stockholder Equity = 26.00b (last 4 quarters mean from totalStockholderEquity)
RoA = 3.50% (Net Income 2.45b / Total Assets 71.49b)
RoE = 9.43% (Net Income TTM 2.45b / Total Stockholder Equity 26.00b)
RoCE = 8.13% (EBIT 3.51b / Capital Employed (Equity 26.00b + L.T.Debt 17.22b))
RoIC = 5.41% (NOPAT 2.53b / Invested Capital 46.74b)
WACC = 4.73% (E(75.36b)/V(97.76b) * Re(6.08%) + D(22.40b)/V(97.76b) * Rd(0.24%) * (1-Tc(0.28)))
Discount Rate = 6.08% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: -100.0 | Cagr: -2.68%
[DCF] Terminal Value 85.93% ; FCFF base≈3.35b ; Y1≈3.22b ; Y5≈3.15b
[DCF] Fair Price = 57.82 (EV 94.40b - Net Debt 20.28b = Equity 74.12b / Shares 1.28b; r=5.90% [WACC]; 5y FCF grow -5.18% → 2.90% )
EPS Correlation: -10.68 | EPS CAGR: -4.03% | SUE: 0.44 | # QB: 0
Revenue Correlation: 81.61 | Revenue CAGR: 8.37% | SUE: 2.15 | # QB: 1
EPS next Quarter (2026-06-30): EPS=0.69 | Chg7d=+0.000 | Chg30d=+0.000 | Revisions Net=-10 | Analysts=16
EPS current Year (2026-12-31): EPS=3.04 | Chg7d=+0.000 | Chg30d=-0.024 | Revisions Net=-22 | Growth EPS=+4.3% | Growth Revenue=+3.1%
EPS next Year (2027-12-31): EPS=3.39 | Chg7d=-0.004 | Chg30d=-0.013 | Revisions Net=-9 | Growth EPS=+11.3% | Growth Revenue=+3.2%
[Analyst] Revisions Ratio: -0.83 (1 Up / 11 Down within 30d for Next Quarter)
[Growth] Implied Growth Rate = 4.7% (Discount Rate 7.9% - Earnings Yield 3.2%)
[Growth] Growth Spread = -2.4% (Analyst 2.3% - Implied 4.7%)